Everything below concerns synaptogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Also in attendance was Nikita Khrushchev of the Soviet Union. July 27: Austria becomes an independent country after the end of the Allied occupation. The last allied troops leave the country in October. August 15: The First Sudanese Civil War begins between the north and the south. November 1: MAAG Vietnam is organized, often regarded as the starting point of the Vietnam War.
She said the Daxor donor of the sperm that she used had lied significantly about his education, and had failed to disclose that he was diagnosed with ADHD, did not speak until age 3, and attended a special school for children with learning and emotional disabilities; she said using his sperm led to both of her children being diagnosed with autism.
=== EC 2.7.7: Nucleotidyltransferases === EC 2.7.7.1: nicotinamide-nucleotide adenylyltransferase EC 2.7.7.2: FAD synthase EC 2.7.7.3: pantetheine-phosphate adenylyltransferase EC 2.7.7.4: sulfate adenylyltransferase EC 2.7.7.5: sulfate adenylyltransferase (ADP) EC 2.7.7.6: DNA-directed RNA polymerase EC 2.7.7.7: DNA-directed DNA polymerase EC 2.7.7.8: polyribonucleotide nucleotidyltransferase EC 2.7.7.9: UTP—glucose-1-phosphate uridylyltransferase EC 2.7.7.10: UTP—hexose-1-phosphate uridylyltransferase EC 2.7.7.11: UTP—xylose-1-phosphate uridylyltransferase EC 2.7.7.12: UDP-glucose—hexose-1-phosphate uridylyltransferase EC 2.7.7.13: mannose-1-phosphate guanylyltransferase EC 2.7.7.14: ethanolamine-phosphate cytidylyltransferase EC 2.7.7.15: choline-phosphate cytidylyltransferase EC 2.7.7.16: Now EC 4.6.1.18, pancreatic ribonuclease EC 2.7.7.17: Now EC 4.6.1.19, ribonuclease T2 EC 2.7.7.18: nicotinate-nucleotide adenylyltransferase EC 2.7.7.19: polynucleotide adenylyltransferase EC 2.7.7.20: deleted (identical with EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.21: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.22: mannose-1-phosphate guanylyltransferase (GDP) EC 2.7.7.23: UDP-N-acetylglucosamine diphosphorylase EC 2.7.7.24: glucose-1-phosphate thymidylyltransferase EC 2.7.7.25: Now EC 2.7.7.72, CCA tRNA nucleotidyltransferase EC 2.7.7.26: Now EC 4.6.1.24, ribonuclease T1 EC 2.7.7.27: glucose-1-phosphate adenylyltransferase EC 2.7.7.28: nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.29: identical to EC 2.7.7.28, nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase EC 2.7.7.30: fucose-1-phosphate guanylyltransferase EC 2.7.7.31: DNA nucleotidylexotransferase EC 2.7.7.32: galactose-1-phosphate thymidylyltransferase EC 2.7.7.33: glucose-1-phosphate cytidylyltransferase EC 2.7.7.34: glucose-1-phosphate guanylyltransferase EC 2.7.7.35: ribose-5-phosphate adenylyltransferase EC 2.7.7.36: aldose-1-phosphate adenylyltransferase EC 2.7.7.37: aldose-1-phosphate nucleotidyltransferase EC 2.7.7.38: 3-deoxy-manno-octulosonate cytidylyltransferase EC 2.7.7.39: glycerol-3-phosphate cytidylyltransferase EC 2.7.7.40: D-ribitol-5-phosphate cytidylyltransferase EC 2.7.7.41: phosphatidate cytidylyltransferase EC 2.7.7.42: [glutamine synthetase] adenylyltransferase EC 2.7.7.43: N-acylneuraminate cytidylyltransferase EC 2.7.7.44: glucuronate-1-phosphate uridylyltransferase EC 2.7.7.45: guanosine-triphosphate guanylyltransferase EC 2.7.7.46: gentamicin 2′′-nucleotidyltransferase EC 2.7.7.47: streptomycin 3′′-adenylyltransferase EC 2.7.7.48: RNA-directed RNA polymerase EC 2.7.7.49: RNA-directed DNA polymerase EC 2.7.7.50: mRNA guanylyltransferase EC 2.7.7.51: adenylylsulfate—ammonia adenylyltransferase EC 2.7.7.52: RNA uridylyltransferase EC 2.7.7.53: ATP adenylyltransferase EC 2.7.7.54: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.55: The activity is part of EC 6.3.2.40, cyclopeptine synthase EC 2.7.7.56: tRNA nucleotidyltransferase EC 2.7.7.57: N-methylphosphoethanolamine cytidylyltransferase EC 2.7.7.58: Now included in EC 6.2.1.71, 2,3-dihydroxybenzoate[aryl-carrier protein] ligase EC 2.7.7.59: [protein-PII] uridylyltransferase EC 2.7.7.60: 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase EC 2.7.7.61: citrate lyase holo-[acyl-carrier protein] synthase EC 2.7.7.62: adenosylcobinamide-phosphate guanylyltransferase EC 2.7.7.63: Now EC 6.3.1.20, lipoate—protein ligase EC 2.7.7.64: UTP-monosaccharide-1-phosphate uridylyltransferase EC 2.7.7.65: diguanylate cyclase EC 2.7.7.66: malonate decarboxylase holo-[acyl-carrier protein] synthase EC 2.7.7.67: CDP-2,3-bis-(O-geranylgeranyl)-sn-glycerol synthase EC 2.7.7.68: 2-phospho-L-lactate guanylyltransferase EC 2.7.7.69: GDP-L-galactose/GDP-D-glucose: hexose 1-phosphate guanylyltransferase EC 2.7.7.70: D-glycero-β-D-manno-heptose 1-phosphate adenylyltransferase EC 2.7.7.71: D-glycero-α-D-manno-heptose 1-phosphate guanylyltransferase EC 2.7.7.72: CCA tRNA nucleotidyltransferase EC 2.7.7.73: sulfur carrier protein ThiS adenylyltransferase EC 2.7.7.74: 1L-myo-inositol 1-phosphate cytidylyltransferase EC 2.7.7.75: molybdopterin adenylyltransferase EC 2.7.7.76: molybdenum cofactor cytidylyltransferase EC 2.7.7.77: molybdenum cofactor guanylyltransferase EC 2.7.7.78: GDP-D-glucose phosphorylase EC 2.7.7.79: tRNAHis guanylyltransferase EC 2.7.7.80: molybdopterin-synthase adenylyltransferase EC 2.7.7.81: pseudaminic acid cytidylyltransferase EC 2.7.7.82: CMP-N,N′-diacetyllegionaminic acid synthase EC 2.7.7.83: UDP-N-acetylgalactosamine diphosphorylase EC 2.7.7.84: diadenylate cyclase EC 2.7.7.85: 2′-5′ oligoadenylate synthase EC 2.7.7.86: cyclic GMP-AMP synthase EC 2.7.7.87: L-threonylcarbamoyladenylate synthase EC 2.7.7.88: GDP polyribonucleotidyltransferase EC 2.7.7.89: [glutamine synthetase]-adenylyl-L-tyrosine phosphorylase EC 2.7.7.90: 8-amino-3,8-dideoxy-''manno''-octulosonate cytidylyltransferase EC 2.7.7.91: valienol-1-phosphate guanylyltransferase EC 2.7.7.92: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate cytidylyltransferase EC 2.7.7.93: phosphonoformate cytidylyltransferase EC 2.7.7.94: Now EC 6.2.1.51, 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 2.7.7.95: Now EC 6.2.1.49, long-chain fatty acid adenylyltransferase FadD28 EC 2.7.7.96: ADP-D-ribose pyrophosphorylase EC 2.7.7.97: 3-hydroxy-4-methylanthranilate adenylyltransferase EC 2.7.7.98: Now EC 6.2.1.50, 4-hydroxybenzoate adenylyltransferase FadD22 EC 2.7.7.99: N-acetyl-α-D-muramate 1-phosphate uridylyltransferase EC 2.7.7.100: SAMP-activating enzyme EC 2.7.7.101: DNA primase DnaG EC 2.7.7.102: DNA primase AEP EC 2.7.7.103: L-glutamine-phosphate cytidylyltransferase EC 2.7.7.104: 2-hydroxyethylphosphonate cytidylyltransferase EC 2.7.7.105: phospho''enol''pyruvate guanylyltransferase EC 2.7.7.106: 3-phospho-D-glycerate guanylyltransferase
David Kossoff (24 November 1919 – 23 March 2005) was a British actor. In 1954 he won the BAFTA Award for Most Promising Newcomer to Leading Film Roles for his appearance as Geza Szobek in The Young Lovers. He played Alf Larkin in TV sitcom The Larkins and Professor Kokintz in The Mouse that Roared (1959) and its sequel The Mouse on the Moon (1963). Because of the drug use of his son Paul, former guitarist of blues-rock band Free, later with Back Street Crawler, who subsequently died, he became an anti-drug campaigner. In 1971 he was also actively involved in the Nationwide Festival of Light, an organisation protesting against the commercial exploitation of sex and violence, and advocating the teachings of Christ as the key to re-establishing moral stability in Britain.
D-dimer (or D dimer) is a dimer that is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link, hence forming a protein dimer. D-dimer concentration may be determined by a blood test to help diagnose thrombosis. Since its introduction in the 1990s, it has become an important test performed in people with suspected thrombotic disorders, such as venous thromboembolism. While a negative result practically rules out thrombosis, a positive result can indicate thrombosis but does not exclude other potential causes. Its main use, therefore, is to exclude thromboembolic disease where the probability is low. D-dimer levels are used as a predictive biomarker for the blood disorder disseminated intravascular coagulation and in the coagulation disorders associated with COVID-19 infection. A four-fold increase in the protein is an indicator of poor prognosis in people hospitalized with COVID-19.
Sources: en.wikipedia.org
Later work confirmed the core message: lichenised fungi are polyphyletic, and the symbiosis has arisen repeatedly in fungal evolution. A 2016–2017 global synthesis of lichen‑forming fungi organized the available multigene evidence into a single cladogram. It shows that the 19,409 then-recognized lichenised species—distributed among 1,002 genera and 119 families—are scattered across 40 orders in eight fungal classes. Almost four‑fifths of the species (roughly 15,000) belong to Lecanoromycetes, but sizeable lichen lineages also sit in Arthoniomycetes, Eurotiomycetes, Dothideomycetes and Lichinomycetes, while three much smaller lineages appear in Agaricomycetes and Coniocybomycetes (Basidiomycota) and in Sordariomycetes (Ascomycota). The pattern confirms that lichenization evolved repeatedly and that "lichen" is an ecological strategy rather than a single evolutionary lineage.
Following TNF-R1 and Fas activation in mammalian cells a balance between proapoptotic (BAX, BID, BAK, or BAD) and anti-apoptotic (Bcl-Xl and Bcl-2) members of the Bcl-2 family are established. This balance is the proportion of proapoptotic homodimers that form in the outer-membrane of the mitochondrion. The proapoptotic homodimers are required to make the mitochondrial membrane permeable for the release of caspase activators such as cytochrome c and SMAC. Control of proapoptotic proteins under normal cell conditions of nonapoptotic cells is incompletely understood, but in general, Bax or Bak are activated by the activation of BH3-only proteins, part of the Bcl-2 family.
Two different kinds of blank may be measured: a sample of dead carbon that has undergone no chemical processing, to detect any machine background, and a sample known as a process blank made from dead carbon that is processed into target material in exactly the same way as the sample which is being dated. Any 14C signal from the machine background blank is likely to be caused either by beams of ions that have not followed the expected path inside the detector or by carbon hydrides such as 12CH2 or 13CH. A 14C signal from the process blank measures the amount of contamination introduced during the preparation of the sample. These measurements are used in the subsequent calculation of the age of the sample.
==== Biological metals reclamation ==== For the biological metals reclamation or bio-leaching, the process uses microorganisms to digest metal oxides selectively. Then, recyclers can reduce these oxides to produce metal nanoparticles. Although bio-leaching has been used successfully in the mining industry, this process is still nascent to the recycling industry and plenty of opportunities exists for further investigation.
When Winston Churchill became Prime Minister in 1940, he bypassed the War Office altogether, and appointed himself Minister of Defence (though there was, curiously, no ministry of defence until 1947). Clement Attlee continued this arrangement when he came to power in 1945, but appointed a separate Minister of Defence for the first time in 1947. In 1964, the present form of the Ministry of Defence was established, unifying the War Office, Admiralty, and Air Ministry.
Sources: en.wikipedia.org
=== Toluene hydrodealkylation === Toluene hydrodealkylation converts toluene to benzene. In this hydrogen-intensive process, toluene is mixed with hydrogen, then passed over a chromium, molybdenum, or platinum oxide catalyst at 500–650 °C and 20–60 atm pressure. Sometimes, higher temperatures are used instead of a catalyst (at the similar reaction condition). Under these conditions, toluene undergoes dealkylation to benzene and methane:
=== Alzheimer's === Neurodegenerative diseases occur from loss of neuronal structure and function. This progressive degeneration of neurons is irreversible. Alzheimer's is a neurodegenerative disease that begins with short-term memory loss progressing to loss of control over heartbeat and breathing. It has been over 100 years since Alois Alzheimer first presented the world disease to the world in 1906. There is evidence for the efficacy of intranasal delivery to treat Alzheimer's. Intranasal delivery of insulin showed greater memory improvement in patients with Alzheimer's than in healthy individuals. Increased microglial activation inflammation are characteristics of Alzheimer's. Animal studies show intranasal administration of pro-resolving lipid mediators decreased both factors, slowing pathogenesis of this disease. Delivering a novel peptide via intranasal route reduced amyloid beta plaques, a defining trait of Alzheimer's and enhanced cognitive functions. Intranasal delivery of anti-Alzheimer's drug dispersed through hydrogel in rabbits demonstrated higher bioavailability compared to oral tablets. MiR132 is an RNA molecule that regulates neuronal morphology and maintains survival. This molecule is downregulated with Alzheimer's. A study administered PEG-PLA nanoparticles loaded with this miRNA to mice through the nasal route. This novel therapy showed increased expression of miR132 and improved memory function.
RSH + Cl–S–C(=O)–Cl → RS–S–C(=O)–Cl + HClThese reagents are useful for the derivatization of biological thiols. Methoxycarbonylsulfenyl chloride, a related reagent derived from the above chemistry, is used in solid-phase peptide synthesis for selective disulfide bond formation via conversion of the acetamidomethyl (Acm) cysteine protecting group to thiol-labile S-alkylsulfenyl thiocarbonate (carbomethylsulfenyl, Scm) protecting group.
=== Opioid receptors === A genetic basis for the efficacy of opioids in the treatment of pain has been demonstrated for several specific variations, but the evidence for clinical differences in opioid effects is not clear. There is an estimated 50% genetic contribution to opioid use disorder. The pharmacogenomics of the opioid receptors and their endogenous ligands have been the subject of intensive activity in association studies. These studies test broadly for a number of phenotypes, including opioid dependence, cocaine dependence, alcohol dependence, methamphetamine dependence/psychosis, response to naltrexone treatment, personality traits, and others. Major and minor variants have been reported for every receptor and ligand coding gene in both coding sequences, as well as regulatory regions. Research on endogenous opioid receptors has focused around the OPRM1 gene, which encodes the μ-opioid receptor, and the OPRK1 and OPRD1 genes, which encode the κ and δ receptors, respectively. Newer approaches shift away from analysis of specific genes and regions to screen the entire genome. These GWAS studies have yielded a number of implicated genes, although many of them code for seemingly unrelated proteins in processes such as cell adhesion, transcriptional regulation, cell structure determination, and RNA, DNA, and protein handling/modifying.
Stimulated by a severe epidemic, variolation was first employed in North America in 1721. The procedure had been known in Boston since 1706, when preacher Cotton Mather learned it from Onesimus, a man he held as a slave, who – like many of his peers – had been inoculated in Africa before they were kidnapped. This practice was widely criticized at first. However, a limited trial showed six deaths that had occurred out of 244 were variolated (2.5%), while 844 out of 5980 died of natural disease (14%), and the process was widely adopted throughout the colonies. The inoculation technique was documented as having a mortality rate of only one in a thousand. Two years after Kennedy's description appeared, March 1718, Dr. Charles Maitland successfully inoculated the five-year-old son of the British ambassador to the Turkish court under orders from the ambassador's wife Lady Mary Wortley Montagu, who four years later introduced the practice to England. An account from letter by Lady Mary Wortley Montagu to Sarah Chiswell, dated 1 April 1717, from the Turkish Embassy describes this treatment:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.